Methods: A total of 123 patients (108 males, 15 females; mean age: 62.2±8.5 years; range, 42 to 78 years) with an EF of 35% or lower who underwent on-pump CABG were included in the retrospective study between December 2022 and December 2023. The patients were divided into two groups according to the type of cardioplegia used: Group 1 (n=74) was designated as the BC group, and Group 2 (n=49) was designated as the DNC group. The groups were compared in terms of aortic cross-clamp duration, cardiopulmonary bypass (CPB) duration, need for defibrillation during weaning from CPB, positive inotrope requirement, intra-aortic balloon pump requirement, postoperative troponin-I levels, postoperative atrial fibrillation occurence, postoperative prolonged ventilation, development of postoperative neurologic complications, need for reintervention due to postoperative bleeding, postoperative transfusion requirement, and EF values at one month after the operation.
Results: There was no significant difference between the two groups in the terms of aortic cross-clamp and CPB duration (p=0.955 vs. p=0.816). Additionally, there was no significant difference in the need for intra-aortic balloon pump usage between the two groups (p=0.105). Dopamine and dobutamine usage were significantly lower in Group 2 (p=0.04 and p=0.05, respectively). The intraoperative requirement for defibrillation was significantly lower in Group 2 (p=0.01). In addition, troponin levels at 12 h postoperatively were significantly lower in Group 2 (p=0.03). The incidence of postoperative atrial fibrillation was significantly lower in Group 2 (p=0.02). Moreover, there was no significant difference in EF values at one month after the operation (p=0.08).
Conclusion: In patients who underwent CABG with reduced EF, modified DNC provided myocardial protection comparable to classic BC. Additionally, the need for intraoperative defibrillation and postoperative inotropic agents, as well as the incidence of postoperative atrial fibrillation, were lower in patients operated with DNC.
The commonly used blood cardioplegia (BC) can be both antegradely and retrogradely administered according to the Buckberg protocol.[4] Blood cardioplegia exerts its effect by inducing diastolic arrest by inhibiting hyperkalaemia-induced repolarization in myocytes. During arrest, BC also leads to intracellular sodium and calcium accumulation,[5] and dosage repetition is required every 15 to 20 min.
Del Nido cardioplegia (DNC), discovered in the 1990s by del Nido to prevent reperfusion injury in pediatric cardiac surgery, has gained widespread use in adult cardiac surgery due to its ability to provide myocardial protection for up to 90 min, reduce dilution when used in a single dose, reduce potassium content, prolong the refractory period of myocytes, extend arrest duration by adding lidocaine (a sodium channel blocker), and mitigate energy consumption by preventing intracellular calcium and sodium accumulation through the sodium channel blockade facilitated by DNC.[6]
Low left ventricular function is an independent risk factor for mortality and morbidity after coronary artery bypass grafting (CABG).[7] While complete revascularization represents the initial step in ensuring adequate myocardial protection, the myocardial protection techniques employed during the intraoperative period also influence the success of the surgery in the early postoperative period.
Although there is information available regarding the use of DNC in adult cardiac surgery, there is limited data on the use of DNC in CABG patients with low ejection fraction (EF). Thus, this study aimed to investigate whether there are differences between BC and DNC in terms of aortic cross-clamp (XCL) duration, CPB duration, defibrillation requirement, inotropic requirement, intra-aortic balloon pump (IABP) requirement, postoperative troponin-I levels, and EF at one month after the operation in CABG patients.
The same surgical technique was applied to all patients, beginning with a median sternotomy, followed by harvesting of the pedicled left internal mammary artery. Subsequently, all patients underwent anastomosis to the left anterior descending coronary artery. The saphenous vein graft was used for anastomosis to other coronary arteries. Del Nido cardioplegia was administered at a total volume of 1000 mL, using a one-to-four ratio with blood (200 mL blood and 800 mL DNC), with 600 mL antegradely administered, and 400 mL retrogradely administered at a temperature of 4°C. If the XCL duration exceeded 60 min, a repeat dose was administered.
On the other hand, BC was administered in a total volume of 1500 to 2000 mL in a four-to-one ratio with blood. It was applied antegradely and retrogradely during XCL, repeated every 15 to 20 min, and maintained at a temperature of 4°C. In addition, topical hypothermia was used in both DNC and BC groups according to the surgeon's preference. Cardiopulmonary bypass flow was maintained at 2.2 to 2.4 L/min/m2 and under mild hypothermia (30 to 32º). All operations were performed by two teams of surgeons, and the anesthesia method utilized was standardized for all patients. The cardioplegia formulations utilized in both groups are depicted in Table 1.
Table 1: Composition of del Nido cardioplegia and blood cardioplegia
The durations of both XCL and CPB, post-XCL inotropic requirement, and IABP requirements were obtained by reviewing patients" operative records. In instances where the systolic arterial pressure did not reach or exceed 90 mmHg (and the mean arterial pressure did not surpass 60 mmHg) upon weaning from CPB, inotropic agents were administered. The primary inotropic agent employed in our clinic was dopamine at a dosage of 5 mcg/kg/min. Should this dosage fail to achieve sufficient hemodynamic stability, supplementary agents were introduced. The dosage of inotropic agents was meticulously adjusted based on hemodynamic parameters (systolic arterial pressure, urine output, and lactate levels in arterial blood gas) throughout the period of intensive care monitoring following CPB separation.
Troponin-I levels were evaluated at postoperative 12 h and on the first postoperative day. Ejection fraction values were assessed at the one-month follow-up using transthoracic echocardiography. Preoperative data were obtained by scanning the hospital database. Postoperative prolonged ventilation, postoperative neurological complications, postoperative bleeding, and postoperative hemodialysis requirement data were obtained from the intensive care unit database.
Statistical analysis
Data were analyzed using IBM SPSS version
25.0 software (IBM Corp., Armonk, NY, USA).
Normally distributed continuous variables were
displayed as mean ± standard deviation (SD), and
blood cardioplegia and del Nido cardioplegia groups were compared using the independent sample t-test.
Categorical variables were expressed as percentages
and frequencies and were compared between groups
using the chi-square test. A p-value <0.05 was
considered statistically significant.
Table 2: Demographic characteristics of the patients
The operative data of the patients were compared. There was no significant difference between the two groups in terms of body surface area, XCL duration, CPB duration, number of bypasses performed, and the need for IABP during separation from CPB. A comparison of the inotropic agent support between the two groups revealed that Group 2 had significantly lower requirements for dopamine and dobutamine (p=0.04 and p=0.05, respectively), while the requirements for adrenaline and noradrenaline were similar in both groups (p=0.654 and p=0.935, respectively). Moreover, the need for intraoperative defibrillation was significantly lower in Group 2 (p=0.01). The comparison of intraoperative data between the groups is presented in Table 3. No differences were observed between the DNC and BC groups in terms of postoperative neurological complications, prolonged ventilation, need for hemodialysis, requirement for postoperative exploration due to bleeding, and development of low cardiac output syndrome.
Table 3: Operative data of the patients
A comparison of the postoperative data of the
patients revealed that there was no significant
difference between the groups in terms of
postoperative CRP levels, troponin values on the
first postoperative day, duration of intensive care
unit stay, duration of hospital stay, and mortality.
However, Group 2 had lower transfusion rates
(p=0.03). In addition, troponin values at 12 h
postoperatively and incidence of postoperative atrial
fibrillation were significantly lower in the DNC
group (p=0.032 and p=0.034, respectively). The postoperative data of the patients are presented in
Table
We evaluated the intraoperative and early postoperative effects of DNC in patients with impaired left ventricular function. Our study demonstrated that in patients undergoing CABG with low EF and high risk, DNC is as effective and reliable in terms of myocardial protection as BC. In addition, patients treated with DNC were found to require less defibrillation, which may suggest that the occurrence of ventricular fibrillation following the removal of the cross-clamp is related to the myocardial ATP (adenosine triphosphate) reserves not being fully replenished. These patients also had lower requirements for inotropic agents, such as dopamine and dobutamine, showed no difference in the use of adrenaline and noradrenaline, and had a similar rate of IABP requirement compared to those who received BC. Undoubtedly, complete revascularization following CPB is the most significant inotropic factor. However, patients with compromised ventricular function may require inotropic agents, primarily dopamine and dobutamine. In our study, patients administered with DNC demonstrated a reduced need for dopamine and dobutamine. We attribute this finding to the DNC's capacity to decrease energy consumption.[6]
In addition, the incidence of postoperative atrial fibrillation was lower, and troponin-I levels at 12 h postoperatively were lower in the DNC group. Moreover, there was no difference in EF values at the one-month follow-up in both groups. Considering all results together, we can conclude that DNC offers promising results and sufficient safety in patients with impaired EF.
While the importance of complete revascularization in CABG patients is undisputed, myocardial protection is also crucial. In patients with impaired ventricular function, the effectiveness of cardioplegic solutions used for myocardial protection is of great interest to researchers. Furthermore, the durations of CPB and XCL are independent risk factors for morbidity and mortality in open heart surgery.[10] One of the key reasons for the current increase in the use of DNC in adult cardiac surgery is that it reduces the durations of CPB and XCL.[11] It was also emphasized that surgical flow and procedure concentration are not disrupted with DNC use[12] and that there is no need for repeat dosing.[13] However, in our study, no difference was found between the two groups in terms of the CPB duration and XCL time. The reasons for this result may be attributed to the fact that all patients in our study had low EF, and another reason could be linked to the distinct surgical teams involved. Furthermore, no difference was observed between the two groups in terms of intensive care unit and hospital stays and mortality rates. These results indicate that DNC is as safe as BC in patients with low EF. Another reason that led us to this conclusion is the lower troponin levels at 12 h postoperatively in patients treated with DNC. In addition, no differences were observed between DNC and BC groups in terms of postoperative neurological complications, prolonged ventilation, need for hemodialysis, requirement for postoperative exploration due to bleeding, and development of low cardiac output syndrome. However, postoperative atrial fibrillation was observed at lower rates in patients treated with DNC, which is consistent with the findings in numerous studies.[8,9,12] When the need for inotropic agents was examined, it was evident that patients treated with DNC had significantly lower requirements for inotropes. This result is consistent with other studies on DNC.[8-14] Another advantage of DNC is that it is inherently administered in much lower volumes compared to BC, thereby resulting in lower hemodilution.[14] The lower volume administered can affect the rates of postoperative transfusion.[15] However, in our study, no difference was found in postoperative red blood cell transfusion rates between two groups.
Despite advances in medical therapy, advanced surgical techniques, and contemporary postoperative care in CABG surgery, low EF remains a risk factor for mortality and morbidity.[13-17] One of the major aspects of debate surrounding DNC is the lack of consensus due to the absence of randomized trials providing conclusive evidence in this regard. Additionally, to the best of our knowledge, there is no study to date that fully demonstrates the efficacy of DNC in myocardial protection at the molecular level in CABG patients. However, researchers have demonstrated that DNC can provide adequate and homogenous distribution of cardioplegia in the ischemic myocardium in patients with coronary artery disease.[18]
This study had several limitations. First, the study was retrospective in design. Another significant limitation was the lack of randomization across groups due to the surgeon-determined selection of cardioplegia, leading to bias in patient selection. Additionally, a significant limitation was the involvement of two different surgical teams.
In conclusion, there is no definitive information regarding the use of del Nido cardioplegia in patients with impaired ventricular function. This study suggests that del Nido cardioplegia is as safe as blood cardioplegia, as evidenced by lower postoperative troponin levels, reduced incidence of postoperative atrial fibrillation, and decreased need for dopamine and dobutamine in patients who received del Nido cardioplegia. Although not entirely conclusive, lower postoperative troponin levels in patients receiving del Nido cardioplegia may suggest that more effective myocardial protection is achieved.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Author Contributions: Hypothesis writng: M.E.E.; Writing: D.S.B.; Data collection: İ.C.; Statistical analysis: S.Ö.; Checkingwriting: U.M.
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Funding: The authors received no financial support for the research and/or authorship of this article.
1) Flack JE 3rd, Cook JR, May SJ, Lemeshow S, Engelman
RM, Rousou JA, et al. Does cardioplegia type affect
outcome and survival in patients with advanced left
ventricular dysfunction? Results from the CABG Patch
Trial. Circulation 2000;102(19 Suppl 3):III84-9. doi:10.1161/01.cir.102.suppl_3.iii-84.
2) Yamamoto H, Yamamoto F. Myocardial protection in cardiac
surgery: A historical review from the beginning to the
current topics. Gen Thorac Cardiovasc Surg 2013;61:485-96.
doi: 10.1007/s11748-013-0279-4.
3) Sá MP, Rueda FG, Ferraz PE, Chalegre ST, Vasconcelos
FP, Lima RC. Is there any difference between blood and
crystalloid cardioplegia for myocardial protection during
cardiac surgery? A meta-analysis of 5576 patients from
36 randomized trials. Perfusion 2012;27:535-46. doi:10.1177/0267659112453754.
4) Ziazadeh D, Mater R, Himelhoch B, Borgman A, Parker
JL, Willekes CL, et al. Single-dose del Nido cardioplegia
in minimally invasive aortic valve surgery. Semin Thorac
Cardiovasc Surg 2017:S1043-067930287-3. doi: 10.1053/j.
semtcvs.2017.10.001.
5) Dobson GP, Jones MW. Adenosine and lidocaine: A new
concept in nondepolarizing surgical myocardial arrest,
protection, and preservation. J Thorac Cardiovasc Surg
2004;127:794-805. doi: 10.1016/s0022-5223(03)01192-9.
6) Brown S, Nassar K, Razzouk J, Kashyap AK, Won M,
Shehadeh T, et al. Outcomes of coronary artery bypass
surgery using modified del Nido cardioplegia in patients with
poor ventricular function. J Cardiothorac Surg 2023;18:346.
doi: 10.1186/s13019-023-02466-0.
7) Matte GS, del Nido PJ. History and use of del Nido
cardioplegia solution at Boston Children's Hospital. J Extra
Corpor Technol 2012;44:98-103.
8) Vickneson K, Chan SP, Li Y, Bin Abdul Aziz MN, Luo HD,
Kang GS, et al. Coronary artery bypass grafting in patients
with low ejection fraction: What are the risk factors? J
Cardiovasc Surg (Torino) 2019;60:396-405. doi: 10.23736/
S0021-9509.19.10670-2.
9) Timek T, Willekes C, Hulme O, Himelhoch B, Nadeau
D, Borgman A, et al. Propensity matched analysis of
del Nido cardioplegia in adult coronary artery bypass
grafting: Initial experience with 100 consecutive patients. Ann Thorac Surg 2016;101:2237-41. doi: 10.1016/j.
athoracsur.2015.12.058.
10) Schutz A, Zhang Q, Bertapelle K, Beecher N, Long W, Lee
VV, et al. Del Nido cardioplegia in coronary surgery: A
propensity-matched analysis. Interact Cardiovasc Thorac
Surg 2020;30:699-705. doi: 10.1093/icvts/ivaa010.
11) Salis S, Mazzanti VV, Merli G, Salvi L, Tedesco CC, Veglia
F, et al. Cardiopulmonary bypass duration is an independent
predictor of morbidity and mortality after cardiac surgery.
J Cardiothorac Vasc Anesth 2008;22:814-22. doi: 10.1053/j.
jvca.2008.08.004.
12) Ota T, Yerebakan H, Neely RC, Mongero L, George I,
Takayama H, et al. Short-term outcomes in adult cardiac
surgery in the use of del Nido cardioplegia solution. Perfusion
2016;31:27-33. doi: 10.1177/0267659115599453.
13) Bademci MS, Kocaaslan C, Bayraktar FA, Oztekin A,
Aydin HB, Aydin E. The use of del Nido cardioplegia for
myocardial protection in isolated coronary artery bypass
surgery. Heart Lung Circ 2020;29:301-7.
14) Brown S, Nassar K, Razzouk J, Kashyap AK, Won M,
Shehadeh T, et al. Outcomes of coronary artery bypass
surgery using modified del Nido cardioplegia in patients with
poor ventricular function. J Cardiothorac Surg 2023;18:346.
doi: 10.1186/s13019-023-02466-0.
15) Marzouk M, Lafreniere-Bessi V, Dionne S, Simard S, Pigeon
C, Dagenais F, et al. Transitioning to Del Nido cardioplegia
for all-comers: The next switching gear? BMC Cardiovasc
Disord 2020;20:215. doi: 10.1186/s12872-020-01506-0.
16) Kim WK, Kim HR, Kim JB, Jung SH, Choo SJ, Chung
CH, et al. del Nido cardioplegia in adult cardiac surgery:
Beyond single-valve surgery. Interact Cardiovasc Thorac
Surg 2018;27:81-7. doi: 10.1093/icvts/ivy028.